#USA #Boston #AVEO Oncology #ESMO 2026 #Rilogrotug

AVEO Oncology to Present at ESMO 2026

AVEO Oncology, a subsidiary of LG Chem, has announced exciting news for medical professionals and researchers alike. An abstract focused on rilogrotug, an investigational IgG1 monoclonal antibody, has been accepted for presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, set to take place in Madrid, Spain, from October 23 to 27. This prestigious platform offers AVEO an opportunity to highlight significant advancements in cancer care.

Presentation Highlights

The upcoming presentation will summarize the results from a Phase 1b clinical trial aimed at assessing the safety and tolerability of rilogrotug. This trial, identified by NCT05865535, is vital as it provides initial insights into the potential of this novel treatment in combating cancer cachexia, a condition characterized by severe weight loss and muscle wasting in cancer patients. The details of the presentation are as follows:

• - Title: A Phase 1b dose escalation study of an anti-GDF-15 monoclonal antibody, rilogrotug (also known as AV-380), for cancer cachexia
• - First Author: Dr. Eric Roeland, Oregon Health and Science University
• - Abstract #: 4191
• - Presentation #: 3917P
• - Session: Supportive Care
• - Date & Time: Saturday, October 24, 2026, from 12:00 PM to 12:45 PM CEST

Insights from the Study

According to Mike Ferraresso, the President and CEO of AVEO, the data emerging from this study is promising. The results showcase significant improvements not only in the safety and tolerability of rilogrotug but also in patient outcomes. A noteworthy increase in weight gain, enhanced skeletal muscle area, and improved appetite were observed among participants.

Ferraresso expressed enthusiasm regarding these findings, stating, "We are excited to present this Phase 1b data showing the safety and tolerability of rilogrotug. Improvements were also observed in weight gain, skeletal muscle area, and appetite. We are encouraged by these results as we advance toward Phase 2 development of rilogrotug in cancer cachexia to further explore the potential benefit in these patients."

About AVEO Oncology

AVEO Pharmaceuticals, Inc. is dedicated to addressing the unmet needs of patients suffering from cancer. The company is particularly known for its flagship product, FOTIVDA® (tivozanib), which is currently approved for treating advanced renal cell carcinoma in the U.S. With ongoing research and the development of potential treatments in various high-need areas—including the current efforts surrounding rilogrotug—AVEO aims to innovate patient care.

Following its acquisition by LG Chem Life Sciences USA in January 2023, AVEO continues to operate with a focus on developing medicines that improve patients' quality of life in oncology.

The Role of Rilogrotug

Rilogrotug (AV-380) targets the growth differentiation factor 15 (GDF-15), an important biomarker associated with cachexia in cancer patients. Elevated levels of this protein are thought to play a role in the marked weight loss observed in cancer, making rilogrotug an intriguing candidate for therapeutic use.

No doubt, the upcoming ESMO presentation will shed light on the promising developments of rilogrotug and underscore AVEO’s commitment to improving the lives of patients battling cancer.

For more information about AVEO and its clinical programs, visit www.lgchem.com.